Latest & greatest articles for prostate cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer

61. Short term health-related quality-of-life in men with metastatic castration-resistant prostate cancer treated with first-line enzalutamide or abiraterone plus prednisone: A systematic review and meta-analysis Full Text available with Trip Pro

Short term health-related quality-of-life in men with metastatic castration-resistant prostate cancer treated with first-line enzalutamide or abiraterone plus prednisone: A systematic review and meta-analysis Redirecting

2020 European Urology Open Science

62. Oncology control of novel treatment regimens of metastatic low-volume hormone-sensitive prostate cancer: A Bayesian network meta-analysis Full Text available with Trip Pro

Oncology control of novel treatment regimens of metastatic low-volume hormone-sensitive prostate cancer: A Bayesian network meta-analysis Redirecting

2020 European Urology Open Science

63. EAU PCa Guideline Panel: Systematic review of focal ablative therapy for localised prostate cancer compared with standard therapies Full Text available with Trip Pro

EAU PCa Guideline Panel: Systematic review of focal ablative therapy for localised prostate cancer compared with standard therapies Redirecting

2020 European Urology Open Science

64. Antidiabetic Medications and the Risk of Prostate Cancer in Patients with Diabetes Mellitus: A Systematic Review and Meta-analysis Full Text available with Trip Pro

Antidiabetic Medications and the Risk of Prostate Cancer in Patients with Diabetes Mellitus: A Systematic Review and Meta-analysis Inplasy Protocol 463 - INPLASY.COM International Platform of Registered Systematic Review and Meta-analysis Protocols Main Menu Share this: Copyright © 2021 INPLASY.COM Powered by INPLASY.COM

2020 INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols

65. The Association Between Hepatitis C Virus Infection and Renal Cell Cancer, Prostate Cancer, and Bladder Cancer: A Systematic Review and Meta-Analysis Full Text available with Trip Pro

The Association Between Hepatitis C Virus Infection and Renal Cell Cancer, Prostate Cancer, and Bladder Cancer: A Systematic Review and Meta-Analysis The Association Between Hepatitis C Virus Infection and Renal Cell Cancer, Prostate Cancer, and Bladder Cancer: A Systematic Review and Meta-Analysis | Research Square Browse Tools & Services Your Cart This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer (...) review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Research article The Association Between Hepatitis C Virus Infection and Renal Cell Cancer, Prostate Cancer, and Bladder Cancer: A Systematic Review and Meta-Analysis Zhongyu Jian, Yucheng Ma, Hong Li, Kunjie Wang Zhongyu Jian department of urology, institute of urology

2020 Research Square

66. Systematic Review of cost-effectiveness models in prostate cancer: exploring new developments in testing and diagnosis Full Text available with Trip Pro

Systematic Review of cost-effectiveness models in prostate cancer: exploring new developments in testing and diagnosis Systematic Review of cost-effectiveness models in prostate cancer: exploring new developments in testing and diagnosis | Research Square Browse Tools & Services Your Cart This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint (...) on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Research article Systematic Review of cost-effectiveness models in prostate cancer: exploring new developments in testing and diagnosis Edna Keeney, Howard Thom, Emma Turner, Richard M Martin, Josie Morley, Sabina Sanghera Edna Keeney University of Bristol Faculty of Health Sciences Corresponding Author ORCiD: https://orcid.org/0000-0002-4763

2020 Research Square

67. Association between C-reactive protein levels and prognosis in prostate cancer: A meta-analysis involving 13,555 subjects Full Text available with Trip Pro

Association between C-reactive protein levels and prognosis in prostate cancer: A meta-analysis involving 13,555 subjects Inplasy Protocol 411 - INPLASY.COM International Platform of Registered Systematic Review and Meta-analysis Protocols Main Menu Share this: Copyright © 2021 INPLASY.COM Powered by INPLASY.COM

2020 INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols

68. Prognostic factors for overall survival in patients with spinal metastasis secondary to prostate cancer: a systematic review and meta-analysis Full Text available with Trip Pro

Prognostic factors for overall survival in patients with spinal metastasis secondary to prostate cancer: a systematic review and meta-analysis Prognostic factors for overall survival in patients with spinal metastasis secondary to prostate cancer: a systematic review and meta-analysis | Research Square Browse Tools & Services Your Cart See the published version of this article at . This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal (...) . Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Research article Prognostic factors for overall survival in patients with spinal metastasis secondary to prostate cancer: a systematic review and meta-analysis Zhong-yu Gao, Tao Zhang, Hui Zhang, Cheng-gang Pang, Wen-xue Jiang Zhong-yu Gao

2020 Research Square

69. The Clinicopathological Characteristics of Androgen Receptor Splicing Variant 7 (AR-V7) Expression in Patients with Castration Resistance Prostate Cancer: A Systematic Review and Meta‐Analysis Full Text available with Trip Pro

The Clinicopathological Characteristics of Androgen Receptor Splicing Variant 7 (AR-V7) Expression in Patients with Castration Resistance Prostate Cancer: A Systematic Review and Meta‐Analysis The Clinicopathological Characteristics of Androgen Receptor Splicing Variant 7 (AR-V7) Expression in Patients with Castration Resistance Prostate Cancer: A Systematic Review and Meta‐Analysis | Research Square Browse Tools & Services Your Cart This is a preprint, a preliminary version of a manuscript (...) that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Primary research The Clinicopathological Characteristics of Androgen Receptor Splicing Variant 7 (AR-V7) Expression in Patients with Castration Resistance Prostate Cancer: A Systematic

2020 Research Square

70. Prognostic factors for overall survival in patients with spinal metastasis secondary to prostate cancer: a systematic review and meta-analysis Full Text available with Trip Pro

Prognostic factors for overall survival in patients with spinal metastasis secondary to prostate cancer: a systematic review and meta-analysis Prognostic factors for overall survival in patients with spinal metastasis secondary to prostate cancer: a systematic review and meta-analysis | Research Square Browse Tools & Services Your Cart See the published version of this article at . This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal (...) . Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Research article Prognostic factors for overall survival in patients with spinal metastasis secondary to prostate cancer: a systematic review and meta-analysis Zhong-yu Gao, Tao Zhang, Hui Zhang, Cheng-gang Pang, Wen-xue Jiang Zhong-yu Gao

2020 Research Square

71. Can 68Ga-prostate specific membrane antigen positron emission tomography / computerized tomography provide an accurate lymph node staging for patients with medium / high risk prostate cancer? A Diagnostic Meta-Analysis Full Text available with Trip Pro

Can 68Ga-prostate specific membrane antigen positron emission tomography / computerized tomography provide an accurate lymph node staging for patients with medium / high risk prostate cancer? A Diagnostic Meta-Analysis Can 68Ga-prostate specific membrane antigen positron emission tomography / computerized tomography provide an accurate lymph node staging for patients with medium / high risk prostate cancer? A Diagnostic Meta-Analysis | Research Square Browse Tools & Services Your Cart See (...) / computerized tomography provide an accurate lymph node staging for patients with medium / high risk prostate cancer? A Diagnostic Meta-Analysis Lei Peng, Jinze Li, Chuanyang Meng, Jinming Li, Chengyu You, Dandan Tang, Tangqiang Wei, Wei Xiong, Yunxiang Li Lei Peng North Sichuan Medical University Jinze Li North Sichuan Medical University Chuanyang Meng North Sichuan Medical University Jinming Li Affiliated Hospital of North Sichuan Medical College Chengyu You North Sichuan Medical University Dandan Tang

2020 Research Square

72. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. Full Text available with Trip Pro

Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. Injectable luteinizing hormone-releasing hormone agonists (e.g., leuprolide) are the standard agents for achieving androgen deprivation for prostate cancer despite the initial testosterone surge and delay in therapeutic effect. The efficacy and safety of relugolix, an oral gonadotropin-releasing hormone antagonist, as compared with those of leuprolide are not known.In this phase 3 trial, we randomly assigned patients (...) with advanced prostate cancer, in a 2:1 ratio, to receive relugolix (120 mg orally once daily) or leuprolide (injections every 3 months) for 48 weeks. The primary end point was sustained testosterone suppression to castrate levels (<50 ng per deciliter) through 48 weeks. Secondary end points included noninferiority with respect to the primary end point, castrate levels of testosterone on day 4, and profound castrate levels (<20 ng per deciliter) on day 15. Testosterone recovery was evaluated in a subgroup

2020 NEJM

73. Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. Full Text available with Trip Pro

Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. Preliminary trial results showed that enzalutamide significantly improved metastasis-free survival among men who had nonmetastatic, castration-resistant prostate cancer and rapidly increasing prostate-specific antigen (PSA) levels while taking androgen-deprivation therapy. Results from the final analysis of overall survival have not yet been reported.In this double-blind, phase 3 trial, men with nonmetastatic (...) , castration-resistant prostate cancer (defined on the basis of conventional imaging and a PSA doubling time of ≤10 months) who were continuing to receive androgen-deprivation therapy were randomly assigned (in a 2:1 ratio) to receive enzalutamide at a dose of 160 mg or placebo once daily. Overall survival was assessed with a group sequential testing procedure and an O'Brien-Fleming-type alpha-spending function.As of October 15, 2019, a total of 288 of 933 patients (31%) in the enzalutamide group and 178

2020 NEJM

74. Radical prostatectomy versus deferred treatment for localised prostate cancer. (Abstract)

Radical prostatectomy versus deferred treatment for localised prostate cancer. Prostate cancer is a common cancer but is oftentimes slow growing. When confined to the prostate, radical prostatectomy (RP), which involves removal of the prostate, offers potential cure that may come at the price of adverse events. Deferred treatment, involving observation and palliative treatment only (watchful waiting (WW)) or close monitoring and delayed local treatment with curative intent as needed (...) , AUA, and ASCO) until 3 March 2020.We included all randomised controlled trials (RCTs) that compared RP versus deferred treatment in patients with localised prostate cancer, defined as T1-2, N0, M0 prostate cancer.Two review authors independently assessed the eligibility of references and extracted data from included studies. The primary outcome was time to death from any cause; secondary outcomes were: time to death from prostate cancer; time to disease progression; time to metastatic disease

2020 Cochrane

75. Lower Thiol, Glutathione, and Glutathione Peroxidase Levels in Prostate Cancer: A Meta-Analysis Study Full Text available with Trip Pro

Lower Thiol, Glutathione, and Glutathione Peroxidase Levels in Prostate Cancer: A Meta-Analysis Study Lower Thiol, Glutathione, and Glutathione Peroxidase Levels in Prostate Cancer: A Meta-Analysis Study[v1] | Preprints Share this article with Create alert Email: Submit > > > doi: 10.20944/preprints202006.0003.v1 Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed Lower Thiol, Glutathione, and Glutathione Peroxidase Levels in Prostate Cancer: A Meta-Analysis Study (...) * , , , , , , , Version 1 : Received: 1 June 2020 / Approved: 2 June 2020 / Online: 2 June 2020 (09:27:21 CEST) How to cite: Sajjaboontawee, N.; Supasitthumrong, T.; Tunvirachaisakul, C.; Nantachai, K.; Snabboon, T.; Reiche, E.M.V.; Simão, A.N.C.; Maes, M. Lower Thiol, Glutathione, and Glutathione Peroxidase Levels in Prostate Cancer: A Meta-Analysis Study. Preprints 2020 , 2020060003 (doi: 10.20944/preprints202006.0003.v1). Sajjaboontawee, N.; Supasitthumrong, T.; Tunvirachaisakul, C.; Nantachai, K.; Snabboon, T

2020 MDPI AG

76. The EAU – EANM – ESTRO – ESUR – SIOG Guidelines on Prostate Cancer

The EAU – EANM – ESTRO – ESUR – SIOG Guidelines on Prostate Cancer EAU Guidelines: Prostate Cancer | Uroweb › Prostate Cancer Prostate Cancer To access the pdfs & translations of individual guidelines, please as EAU member. Non-EAU members can view the web versions. To become an EAU member, click . N. Mottet (Chair), P. Cornford (Vice-chair), R.C.N. van den Bergh, E. Briers (Patient Representative), M. De Santis, S. Fanti, S. Gillessen, J. Grummet, A.M. Henry, T.B. Lam, M.D. Mason, T.H. van der (...) Kwast, H.G. van der Poel, O. Rouvière, I.G. Schoots, D. Tilki, T. Wiegel Guidelines Associates: T. Van den Broeck, M. Cumberbatch, N. Fossati, G. Gandaglia, N. Grivas, M. Lardas, M. Liew, L. Moris, D.E. Oprea-Lager, P-P.M. Willemse TABLE OF CONTENTS REFERENCES 1. Mottet, N., et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol, 2017. 71: 618. 2. Cornford, P., et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II

2020 European Association of Nuclear Medicine

77. The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Full Text available with Trip Pro

The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients With Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label (...) Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients With Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 The Institute of Cancer Research and Royal Marsden Hospital, London, UK. Electronic address: david.dearnaley@icr.ac.uk. 2 Urology San Antonio, San Antonio, TX, USA. 3 21st Century

2020 EvidenceUpdates

78. External Validation of the 2019 Briganti Nomogram for the Identification of Prostate Cancer Patients Who Should Be Considered for an Extended Pelvic Lymph Node Dissection

External Validation of the 2019 Briganti Nomogram for the Identification of Prostate Cancer Patients Who Should Be Considered for an Extended Pelvic Lymph Node Dissection External Validation of the 2019 Briganti Nomogram for the Identification of Prostate Cancer Patients Who Should Be Considered for an Extended Pelvic Lymph Node Dissection - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History (...) a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Eur Urol Actions . 2020 Apr 5;S0302-2838(20)30198-6. doi: 10.1016/j.eururo.2020.03.023. Online ahead of print. External Validation of the 2019 Briganti Nomogram for the Identification of Prostate Cancer Patients Who Should Be Considered for an Extended Pelvic Lymph Node Dissection

2020 EvidenceUpdates

79. Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study Full Text available with Trip Pro

Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study Effect of Enzalutamide Plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients With Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study - PubMed This site needs JavaScript to work (...) of Life in Patients With Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study , , , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Urology, University Hospital, Eberhard Karls University of Tübingen, Tübingen, Germany. Electronic address: arnulf.stenzl@med.uni-tuebingen.de. 2 Urological Associates of Southern Arizona, Tucson, AZ, USA. 3 Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la

2020 EvidenceUpdates

80. Olaparib for Metastatic Castration-Resistant Prostate Cancer. (Abstract)

Olaparib for Metastatic Castration-Resistant Prostate Cancer. Multiple loss-of-function alterations in genes that are involved in DNA repair, including homologous recombination repair, are associated with response to poly(adenosine diphosphate-ribose) polymerase (PARP) inhibition in patients with prostate and other cancers.We conducted a randomized, open-label, phase 3 trial evaluating the PARP inhibitor olaparib in men with metastatic castration-resistant prostate cancer who had disease (...) with metastatic castration-resistant prostate cancer who had disease progression while receiving enzalutamide or abiraterone and who had alterations in genes with a role in homologous recombination repair, olaparib was associated with longer progression-free survival and better measures of response and patient-reported end points than either enzalutamide or abiraterone. (Funded by AstraZeneca and Merck Sharp & Dohme; PROfound ClinicalTrials.gov number, NCT02987543.).Copyright © 2020 Massachusetts Medical

2020 NEJM